Antigen-presenting cell-mediated immune tolerance pathway (APC-mediated immune tolerance)

The antigen-presenting cell-mediated immune tolerance pathway is a fundamental biological process essential for maintaining peripheral tolerance and preventing autoimmunity (Nature Reviews Immunology, 2017). It involves the presentation of antigens by antigen-presenting cells (APCs), such as dendritic cells or macrophages, in a context that lacks sufficient costimulation (e.g., CD80/CD86) or provides dominant inhibitory signals like PD-L1 and IL-10 (Janeway's Immunobiology, 9th Ed). This interaction leads to T-cell anergy, clonal deletion, or the induction of FoxP3+ regulatory T-cells (Tregs), which suppress further immune responses (Frontiers in Immunology, 2020). In clinical practice, drugs like Abatacept (Orencia) exploit this pathway by mimicking CTLA-4 to block CD28-mediated costimulation, thereby treating autoimmune conditions like rheumatoid arthritis (FDA Label). Conversely, in the oncology setting, tumors often hijack this pathway to create an immunosuppressive microenvironment, making the inhibition of these tolerogenic mechanisms a key goal for checkpoint inhibitor therapies (Science, 2018). Overall, modulating this pathway represents a sophisticated approach to either dampening unwanted immune responses or restoring anti-tumor immunity.

Other names

Tolerogenic antigen presentationAPC-induced peripheral toleranceDendritic cell-mediated toleranceAntigen-specific immune tolerance

Induction of T-cell hyporesponsiveness or regulatory phenotype through antigen presentation in a non-inflammatory or inhibitory context, often involving the blockade of costimulatory signals or the activation of coinhibitory pathways.